New Content Enhances MDL Patent Chemistry Database

Database is now up-to-date, reprocessing of back-files has greatly increased wealth of information in latest release


Frankfurt, Germany – March 1, 2007 – Elsevier MDL is pleased to announce significant progress in the following three ongoing initiatives to enhance patent coverage in the structure-searchable MDL® Patent Chemistry Database.

  • MDL Patent Chemistry Database has always been up-to-date with the three patent classes C07 Organic Chemistry, A01N Agrochemicals/Biocides and C09B Dyes. Now, through an aggressive indexing program made possible by Elsevier, the manual indexing of A61K Pharma patents is also up-to-date

  • Due to the enormous increase in published Pharma A61K patents between 2004 and 2006, some of these patents have not been indexed manually (only automatically). An additional intensive program of increased manual indexing will address these patents in the future. This will have priority over the indexing of non-English-language patents.

  • Database content has increased by fifteen percent since November 2006 through the addition of new compounds and reactions enabled by the automatic reprocessing of back-files with improved indexing software

"The increased coverage provided by MDL Patent Chemistry Database will significantly assist chemistry and life sciences researchers in synthesis planning, bioactivity profiling and patent evaluation," said Dr. Michiel Kolman, Managing Director of MDL Information Systems GmbH. "Elsevier MDL is continuing to invest heavily in this unique database by continually improving automatic and manual indexing capabilities for both new patent information and back-files. Patent Chemistry Database is the only database that provides reactions, physical substance data, including prophetic compounds, and claims text from patent documents as frequently as two weeks after publication."

The new and improved automatic indexing software used in reprocessing the patent back-files provides better name-to-structure processing and improved analysis of reaction procedure texts in multi-step reactions. In the December 2006 database update, this initiative provided approximately 300,000 additional compounds (including 140,000 prophetic compounds) and 150,000 additional high quality, full reactions (with reaction text from original patent documents). With the current March 2007 update, MDL Patent Chemistry Database has grown again by about 300,000 additional substances and 150,000 full reactions. Approximately 100,000 additional prophetic products are offered as product-half-reactions. This means that the database has grown by fifteen percent in the past three months - by more than half a million additional compounds (including 240,000 additional prophetic compounds) and approximately 300,000 full-reactions. 

###

About MDL® Patent Chemistry Database
The Patent Chemistry Database is a powerful, structure-searchable, factual database specifically designed for research scientists that contains chemical reactions, compounds and compound property data from organic chemistry and life science patents (World and European since 1978, United States since 1976). It is the only database to index not only reactions and compounds with data, but also prophetic compounds and analogous reactions mentioned in the patent, for which no specific data (such as yield or spectral data) are given. The March 2007 database update contains approximately 3.4 million chemical reactions with reaction procedure text and approximately 4.2 million organic, inorganic, organometallic (and polymeric) compounds and associated property data. Measured bioassay, application and physical data including spectral peaks are provided for substances. To enable researchers to assess the relevance of patents, citation information is enriched by claims text, Markush structure and reaction display as well as Markush Family. Updated bi-weekly, the MDL Patent Chemistry Database can be searched via MDL® CrossFire® Commander V7.0 SP2 (or SP1) and the DiscoveryGate® content service.

About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful scientific R&D by improving the speed and quality of scientists' decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. For more information, visit www.elsevier.com. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com .


About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contact:
Jean Holt
+1 (925) 543-5400
j.holt@mdl.com